Matrix Metalloproteinase-7
MMP7proteinMMP-7 degrades fibrous-cap collagen and proteoglycans, promoting cap destabilization and rupture, and is elevated in CAD and MI patients.
Pathway placement
Cascade stepFibrous-cap degradation & rupture
Confidencehigh
RationaleMMP-family protease; fibrous-cap extracellular-matrix degradation.
Also acts inVascular inflammation
Druggability
DruggableYes
Known drugs / candidates3
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000137673
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I47
C — confounder / Type-II66
A — assay feasibility72
E — evidence strength25
T1DI (composite)7
Specificity differential (R−C)-18.6
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Human genetic evidence
0.259
Open Targets association (STEMI)
Literature evidence(1)
- Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial.ESC heart failure · 2023 · PMID 37939716 · doi